Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Updated data from the FORTE trial of carfilzomib plus lenalidomide or cyclophosphamide for myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.06.18
Views: 1434

Dr Francesca Gay - University of Torino, Torino, Italy

Dr Gay speaks with ecancer at EHA 2018 about updated data from the FORTE trial, looking at newly diagnosed myeloma patients treated with carfilzomib plus lenalidomide or cyclophosphamide.

She states that one of the primary objectives of the trail was response rate after the induction phase and both regiments of patients were highly effective with roughly 90% of patients in both arms achieving a partial response.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation